Shandong Xinhua Pharmaceutical (000756) Obtains Drug Registration Certificate for Glucosamine Sulfate Capsules

Bulletin Express02-09 16:42

Shandong Xinhua Pharmaceutical Company Limited (referred to as Xinhua Pharmaceutical, stock code: 000756) announced that it has received a Drug Registration Certificate from the National Medical Products Administration for its Glucosamine Sulfate Capsules.

According to the announcement dated 9 February 2026, Glucosamine Sulfate Capsules fall under Class 4 chemicals and will be managed as Category A non-prescription drugs. The product specifications range from 0.25g (based on glucosamine sulfate content) to 0.314g (based on glucosamine sulfate and sodium chloride content). It is primarily indicated for the treatment of primary and secondary osteoarthritis, and it is listed as a Category B product in the “National Drug Catalogue for Basic Medical Insurance, Work Related-Injury Insurance, and Maternity Insurance (2025).” The company noted that sales of similar products in China’s public medical institutions reached approximately RMB 850 million in 2024.

The announcement also highlighted that obtaining the certificate enhances Xinhua Pharmaceutical’s product portfolio and comprehensive competitiveness. However, the company stated that its pharmaceutical sales may be influenced by changes in industry policies, market conditions, and other factors, advising investors to consider such uncertainties carefully.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165499833?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165499833","market":"us","top_or_hot":-1,"title":"Shandong Xinhua Pharmaceutical (000756) Obtains Drug Registration Certificate for Glucosamine Sulfate Capsules","media":"Bulletin Express","content":"<p>Shandong Xinhua Pharmaceutical Company Limited (referred to as Xinhua Pharmaceutical, stock code: 000756) announced that it has received a Drug Registration Certificate from the National Medical Products Administration for its Glucosamine Sulfate Capsules.</p>\n<p>According to the announcement dated 9 February 2026, Glucosamine Sulfate Capsules fall under Class 4 chemicals and will be managed as Category A non-prescription drugs. The product specifications range from 0.25g (based on glucosamine sulfate content) to 0.314g (based on glucosamine sulfate and sodium chloride content). It is primarily indicated for the treatment of primary and secondary osteoarthritis, and it is listed as a Category B product in the “National Drug Catalogue for Basic Medical Insurance, Work Related-Injury Insurance, and Maternity Insurance (2025).” The company noted that sales of similar products in China’s public medical institutions reached approximately RMB 850 million in 2024.</p>\n<p>The announcement also highlighted that obtaining the certificate enhances Xinhua Pharmaceutical’s product portfolio and comprehensive competitiveness. However, the company stated that its pharmaceutical sales may be influenced by changes in industry policies, market conditions, and other factors, advising investors to consider such uncertainties carefully.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Xinhua Pharmaceutical (000756) Obtains Drug Registration Certificate for Glucosamine Sulfate Capsules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Xinhua Pharmaceutical (000756) Obtains Drug Registration Certificate for Glucosamine Sulfate Capsules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-09 16:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shandong Xinhua Pharmaceutical Company Limited (referred to as Xinhua Pharmaceutical, stock code: 000756) announced that it has received a Drug Registration Certificate from the National Medical Products Administration for its Glucosamine Sulfate Capsules.</p>\n<p>According to the announcement dated 9 February 2026, Glucosamine Sulfate Capsules fall under Class 4 chemicals and will be managed as Category A non-prescription drugs. The product specifications range from 0.25g (based on glucosamine sulfate content) to 0.314g (based on glucosamine sulfate and sodium chloride content). It is primarily indicated for the treatment of primary and secondary osteoarthritis, and it is listed as a Category B product in the “National Drug Catalogue for Basic Medical Insurance, Work Related-Injury Insurance, and Maternity Insurance (2025).” The company noted that sales of similar products in China’s public medical institutions reached approximately RMB 850 million in 2024.</p>\n<p>The announcement also highlighted that obtaining the certificate enhances Xinhua Pharmaceutical’s product portfolio and comprehensive competitiveness. However, the company stated that its pharmaceutical sales may be influenced by changes in industry policies, market conditions, and other factors, advising investors to consider such uncertainties carefully.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00719","symbol_name":"山东新华制药股份","start_time":0,"source_url":"","article_id":"1165499833","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165499833","pubTimestamp":1770626579,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shandong Xinhua Pharmaceutical Company Limited (referred to as Xinhua Pharmaceutical, stock code: 000756) announced that it has received a Drug Registration Certificate from the National Medical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00719":"山东新华制药股份"},"translate_title":"山东新华制药（000756）硫酸氨基葡萄糖胶囊获得药品注册证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"Shandong Xinhua Pharmaceutical Company Limited (referred to as Xinhua Pharmaceutical, stock code: 000756) announced that it has received a Drug Registration Certificate from the National Medical Products Administration for its Glucosamine Sulfate Capsules.\nAccording to the announcement dated 9 February 2026, Glucosamine Sulfate Capsules fall under Class 4 chemicals and will be managed as Category A non-prescription drugs. The product specifications range from 0.25g (based on glucosamine sulfate content) to 0.314g (based on glucosamine sulfate and sodium chloride content). It is primarily indicated for the treatment of primary and secondary osteoarthritis, and it is listed as a Category B product in the “National Drug Catalogue for Basic Medical Insurance, Work Related-Injury Insurance, and Maternity Insurance (2025).” The company noted that sales of similar products in China’s public medical institutions reached approximately RMB 850 million in 2024.\nThe announcement also highlighted that obtaining the certificate enhances Xinhua Pharmaceutical’s product portfolio and comprehensive competitiveness. However, the company stated that its pharmaceutical sales may be influenced by changes in industry policies, market conditions, and other factors, advising investors to consider such uncertainties carefully.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165499833","isCrawlerRequest":true}